Synthaverse (WAR:SVE) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


WAR:SVE Synthaverse SA WAR:SVE
55 GF Score
Price zł2.70
GF Value zł3.04
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Synthaverse Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Synthaverse's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

WAR:SVE vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Synthaverse's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synthaverse Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthaverse's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Synthaverse's Margin of Safety % (DCF Earnings Based) falls into.


WAR:SVE
55GF Score
Synthaverse SA WAR:SVE
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synthaverse (WAR:SVE) Overvalued in 2026?

Based on GuruFocus' analysis, Synthaverse stock appears to be undervalued. The current stock price of zł2.70 is trading 11.2% below its estimated GF Value™ of zł3.04. GuruFocus considers Synthaverse to be Modestly Undervalued.

Key valuation signals for WAR:SVE:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: zł3.04 vs. price of zł2.70 (11.2% below fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the WAR:SVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synthaverse Business Description

Other Exchanges 6NQ:Germany
Address 10, Uniwersytecka street, Lublin, POL, 20-029
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
55GF Score

Get the complete analysis for WAR:SVE

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł2.70
Price
zł3.04
GF Value